Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, a leader in genome editing, will participate in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine, a leader in genome editing, will participate in two upcoming investor conferences. The Wells Fargo 2021 Virtual Healthcare Conference is scheduled for September 10, 2021 at 8:00 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021 at 9:30 a.m. ET. Both events will be available via live webcast on the company's website, with archived recordings accessible for about 30 days.
Editas focuses on developing CRISPR-based genomic treatments for serious diseases worldwide.
Details
News Market Reaction – EDIT
The recorded move for EDIT in the trading session of this news was +9.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:
- Wells Fargo 2021 Virtual Healthcare Conference
Fireside Chat (Virtual)
Date: Friday, September 10, 2021
Time: 8:00 a.m. ET
- Morgan Stanley 19th Annual Global Healthcare Conference
Fireside Chat (Virtual)
Date: Tuesday, September 14, 2021
Time: 9:30 a.m. ET
The events will be webcast live and can be accessed on the Editas Medicine website in the Investors section. Archived recordings will be available for approximately 30 days following the events.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investors
Ron Moldaver
(617) 401-9052
ir@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.